212 related articles for article (PubMed ID: 36690453)
1. Natural Course and Prognosis of Primary Spinal Glioblastoma: A Nationwide Study.
Amelot A; Terrier LM; Mathon B; Joubert C; Picart T; Jecko V; Bauchet L; Bernard F; Castel X; Chenin L; Cook AR; Emery E; Figarella-Branger D; Gauchotte G; Graillon T; Jouvet A; Kalamarides M; Knafo S; Lazard A; Lubrano V; Mokhtari K; Rigau V; Roualdes V; Rousseau A; Seizeur R; Uro-Coste E; Voirin J; Metellus P; Pallud J; Zemmoura I;
Neurology; 2023 Apr; 100(14):e1497-e1509. PubMed ID: 36690453
[TBL] [Abstract][Full Text] [Related]
2. Long-term therapy with temozolomide is a feasible option for newly diagnosed glioblastoma: a single-institution experience with as many as 101 temozolomide cycles.
Barbagallo GM; Paratore S; Caltabiano R; Palmucci S; Parra HS; Privitera G; Motta F; Lanzafame S; Scaglione G; Longo A; Albanese V; Certo F
Neurosurg Focus; 2014 Dec; 37(6):E4. PubMed ID: 25434389
[TBL] [Abstract][Full Text] [Related]
3. Accelerated hyperfractionated radiochemotherapy with temozolomide is equivalent to normofractionated radiochemotherapy in a retrospective analysis of patients with glioblastoma.
Lewitzki V; Klement RJ; Kosmala R; Lisowski D; Flentje M; Polat B
Radiat Oncol; 2019 Dec; 14(1):227. PubMed ID: 31831026
[TBL] [Abstract][Full Text] [Related]
4. Survival benefit of levetiracetam in patients treated with concomitant chemoradiotherapy and adjuvant chemotherapy with temozolomide for glioblastoma multiforme.
Kim YH; Kim T; Joo JD; Han JH; Kim YJ; Kim IA; Yun CH; Kim CY
Cancer; 2015 Sep; 121(17):2926-32. PubMed ID: 25975354
[TBL] [Abstract][Full Text] [Related]
5. Age-stratified clinical performance and survival of patients with IDH-wildtype glioblastoma homogeneously treated by radiotherapy with concomitant and maintenance temozolomide.
Berger K; Turowski B; Felsberg J; Malzkorn B; Reifenberger G; Steiger HJ; Budach W; Haussmann J; Knipps J; Rapp M; Hänggi D; Sabel M; Mijderwijk HJ; Kamp MA
J Cancer Res Clin Oncol; 2021 Jan; 147(1):253-262. PubMed ID: 32748120
[TBL] [Abstract][Full Text] [Related]
6. Hypofractionated chemoradiotherapy with temozolomide as a treatment option for glioblastoma patients with poor prognostic features.
Lim YJ; Kim IH; Han TJ; Choi SH; Park SH; Park CK; Paek SH; Lee SH; Kim TM
Int J Clin Oncol; 2015 Feb; 20(1):21-8. PubMed ID: 24705988
[TBL] [Abstract][Full Text] [Related]
7. Impact of removed tumor volume and location on patient outcome in glioblastoma.
Awad AW; Karsy M; Sanai N; Spetzler R; Zhang Y; Xu Y; Mahan MA
J Neurooncol; 2017 Oct; 135(1):161-171. PubMed ID: 28685405
[TBL] [Abstract][Full Text] [Related]
8. Radiotherapy plus temozolomide in elderly patients with glioblastoma: a "real-life" report.
Biau J; Chautard E; De Schlichting E; Dupic G; Pereira B; Fogli A; Müller-Barthélémy M; Dalloz P; Khalil T; Dillies AF; Durando X; Godfraind C; Verrelle P
Radiat Oncol; 2017 Dec; 12(1):197. PubMed ID: 29212499
[TBL] [Abstract][Full Text] [Related]
9. Prognostic implications of the subcellular localization of survivin in glioblastomas treated with radiotherapy plus concomitant and adjuvant temozolomide.
Saito T; Sugiyama K; Takeshima Y; Amatya VJ; Yamasaki F; Takayasu T; Nosaka R; Muragaki Y; Kawamata T; Kurisu K
J Neurosurg; 2018 Mar; 128(3):679-684. PubMed ID: 28430038
[TBL] [Abstract][Full Text] [Related]
10. Prognostic implication of clinical and pathologic features in patients with glioblastoma multiforme treated with concomitant radiation plus temozolomide.
Donato V; Papaleo A; Castrichino A; Banelli E; Giangaspero F; Salvati M; Delfini R
Tumori; 2007; 93(3):248-56. PubMed ID: 17679459
[TBL] [Abstract][Full Text] [Related]
11. Neutrophil-lymphocyte ratio dynamics during concurrent chemo-radiotherapy for glioblastoma is an independent predictor for overall survival.
Mason M; Maurice C; McNamara MG; Tieu MT; Lwin Z; Millar BA; Menard C; Laperriere N; Milosevic M; Atenafu EG; Mason W; Chung C
J Neurooncol; 2017 May; 132(3):463-471. PubMed ID: 28332000
[TBL] [Abstract][Full Text] [Related]
12. Long-term follow-up results of concomitant chemoradiotherapy followed by adjuvant temozolomide therapy for glioblastoma multiforme patients. The importance of MRI information in survival: Single-center experience.
Lukács G; Tóth Z; Sipos D; Csima M; Hadjiev J; Bajzik G; Cselik Z; Semjén D; Repa I; Kovács Á
Ideggyogy Sz; 2018 Mar; 71(3-04):95-103. PubMed ID: 29889468
[TBL] [Abstract][Full Text] [Related]
13. Molecular-Based Recursive Partitioning Analysis Model for Glioblastoma in the Temozolomide Era: A Correlative Analysis Based on NRG Oncology RTOG 0525.
Bell EH; Pugh SL; McElroy JP; Gilbert MR; Mehta M; Klimowicz AC; Magliocco A; Bredel M; Robe P; Grosu AL; Stupp R; Curran W; Becker AP; Salavaggione AL; Barnholtz-Sloan JS; Aldape K; Blumenthal DT; Brown PD; Glass J; Souhami L; Lee RJ; Brachman D; Flickinger J; Won M; Chakravarti A
JAMA Oncol; 2017 Jun; 3(6):784-792. PubMed ID: 28097324
[TBL] [Abstract][Full Text] [Related]
14. Determining a cut-off residual tumor volume threshold for patients with newly diagnosed glioblastoma treated with temozolomide chemoradiotherapy: A multicenter cohort study.
Woo PYM; Ho JMK; Tse TPK; Lam SW; Mak CHK; Chan DTM; Lee MWY; Wong ST; Chan KY; Poon WS
J Clin Neurosci; 2019 May; 63():134-141. PubMed ID: 30712777
[TBL] [Abstract][Full Text] [Related]
15. Treatment of newly diagnosed glioblastoma in the elderly: a network meta-analysis.
Hanna C; Lawrie TA; Rogozińska E; Kernohan A; Jefferies S; Bulbeck H; Ali UM; Robinson T; Grant R
Cochrane Database Syst Rev; 2020 Mar; 3(3):CD013261. PubMed ID: 32202316
[TBL] [Abstract][Full Text] [Related]
16. Super-early initiation of temozolomide prolongs the survival of glioblastoma patients without gross-total resection: a retrospective cohort study.
Jiang H; Zeng W; Ren X; Cui Y; Li M; Yang K; Elbaroody M; Lin S
J Neurooncol; 2019 Aug; 144(1):127-135. PubMed ID: 31175579
[TBL] [Abstract][Full Text] [Related]
17. Shorter survival time of adolescents and young adult patients than older adults with spinal cord glioblastoma: a multicenter study.
Inoue T; Endo T; Muto J; Umebayashi D; Mitsuhara T; Shigekawa S; Kanematsu R; Iwasaki M; Takami T; Hida K; Mizuno M; ;
J Neurosurg Spine; 2024 Feb; 40(2):196-205. PubMed ID: 37976504
[TBL] [Abstract][Full Text] [Related]
18. Performance status during and after radiotherapy plus concomitant and adjuvant temozolomide in elderly patients with glioblastoma multiforme.
Lee JH; Jung TY; Jung S; Kim IY; Jang WY; Moon KS; Jeong EH
J Clin Neurosci; 2013 Apr; 20(4):503-8. PubMed ID: 23313530
[TBL] [Abstract][Full Text] [Related]
19. Predictors of survival and effect of short (40 Gy) or standard-course (60 Gy) irradiation plus concomitant temozolomide in elderly patients with glioblastoma: a multicenter retrospective study of AINO (Italian Association of Neuro-Oncology).
Lombardi G; Pace A; Pasqualetti F; Rizzato S; Faedi M; Anghileri E; Nicolotto E; Bazzoli E; Bellu L; Villani V; Fabi A; Ferrazza P; Gurrieri L; Dall'Agata M; Eoli M; Della Puppa A; Pambuku A; D'Avella D; Berti F; Rudà R; Zagonel V
J Neurooncol; 2015 Nov; 125(2):359-67. PubMed ID: 26423801
[TBL] [Abstract][Full Text] [Related]
20. Dose-dense temozolomide for newly diagnosed glioblastoma: a randomized phase III clinical trial.
Gilbert MR; Wang M; Aldape KD; Stupp R; Hegi ME; Jaeckle KA; Armstrong TS; Wefel JS; Won M; Blumenthal DT; Mahajan A; Schultz CJ; Erridge S; Baumert B; Hopkins KI; Tzuk-Shina T; Brown PD; Chakravarti A; Curran WJ; Mehta MP
J Clin Oncol; 2013 Nov; 31(32):4085-91. PubMed ID: 24101040
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
